BioCryst Pharmaceuticals BCRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $885.72M+75.9% | $874.84M+94.1% | $599.82M+45.4% | $557.51M+45.9% | $503.49M+41.7% | ||
| $19.88M+27.7% | $19.08M+55.5% | $15.65M+102% | $16.67M+197% | $15.57M+223% | ||
| $865.83M+77.5% | $855.76M+95.2% | $584.17M+44.3% | $540.84M+43.6% | $487.91M+39.2% | ||
| 97.8%+0.8pp | 97.8%+0.5pp | 97.4%-0.7pp | 97%-1.5pp | 96.9%-1.7pp | ||
| $189.18M+14.4% | $166.13M-4.9% | $174.7M-10.5% | $171.18M-14.9% | $165.42M-22.9% | ||
| $360.73M+24.7% | $348.65M+30.9% | $333.37M+33.1% | $315.46M+33.7% | $289.33M+28.2% | ||
| $1.27B+170% | $533.85M+17.8% | $523.72M+15.5% | $503.31M+13.7% | $470.31M+5.6% | ||
| -$381.84M-1,251% | $340.99M+13,509% | $76.1M+287% | $54.2M+190% | $33.17M+137% | ||
| -43.1%-49.7pp | 39%+39.5pp | 12.7%+22.6pp | 9.7%+25.5pp | 6.6%+31.9pp | ||
| $75.16M-22.9% | $78.87M-19.9% | $89.19M-9.6% | $94.35M-6.7% | $97.5M-7.4% | ||
| -$72.34M+14.2% | -$73.6M+12.8% | -$82.71M+11.6% | -$86.39M+16.2% | -$84.35M+25.0% | ||
| -$454.18M-787% | $267.39M+408% | -$6.62M+94.7% | -$32.19M+78.0% | -$51.18M+75.5% | ||
| $3.81M+66.4% | $3.53M+83.2% | $2.16M— | $3.52M— | $2.29M— | ||
| -$457.98M-757% | $263.86M+397% | -$8.78M+92.9% | -$35.71M+75.5% | -$53.47M+74.4% | ||
| -51.7%-41.1pp | 30.2%+49.9pp | -1.5%+28.5pp | -6.4%+31.8pp | -10.6%+48.1pp | ||
| -$1.77-581% | $1.21+381% | -$0.05+91.8% | -$0.18+75.3% | -$0.26+75.7% | ||
| -$379.72M-1,202% | $342.38M+26,498% | $77.4M+297% | $55.48M+194% | $34.44M+139% | ||
| -42.9%-49.7pp | 39.1%+39.4pp | 12.9%+22.4pp | 10%+25.3pp | 6.8%+31.7pp | ||
| -$381.84M-1,251% | $340.99M+13,509% | $76.1M+287% | $54.2M+190% | $33.17M+137% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.
- Is BioCryst Pharmaceuticals profitable?
- BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.
- What are BioCryst Pharmaceuticals's profit margins?
- Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.
- What is BioCryst Pharmaceuticals's earnings per share?
- BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.
- Where does BioCryst Pharmaceuticals's income statement data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
